Truist Securities Upgrades Biogen (BIIB) to Buy
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Price: $197.74 -2.67%
Rating Summary:
27 Buy, 16 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 9 | Down: 14 | New: 29
Rating Summary:
27 Buy, 16 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 9 | Down: 14 | New: 29
Join SI Premium – FREE
Truist Securities analyst Danielle Brill upgraded Biogen (NASDAQ: BIIB) from Hold to Buy with a price target of $235.00.
For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.
Shares of Biogen closed at $199.15 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Alphabet Sees FY26 Capex $195B To $205B, Saw $180B To $190B
- Intel mulls partnership for Ohio chip fab, SK Hynix among candidates - report
- Evercore ISI on Google's Q2: bar was high, and GOOGL mostly cleared it
Create E-mail Alert Related Categories
UpgradesRelated Entities
Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
